These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21446041)

  • 1. A galectin-3 sequence polymorphism confers TRAIL sensitivity to human breast cancer cells.
    Mazurek N; Byrd JC; Sun Y; Ueno S; Bresalier RS
    Cancer; 2011 Oct; 117(19):4375-80. PubMed ID: 21446041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between galectin-3 expression and TRAIL sensitivity in breast cancer.
    Amm HM; Buchsbaum DJ
    Expert Rev Anticancer Ther; 2011 Aug; 11(8):1193-6. PubMed ID: 21916572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reconstitution of galectin-3 alters glutathione content and potentiates TRAIL-induced cytotoxicity by dephosphorylation of Akt.
    Lee YJ; Song YK; Song JJ; Siervo-Sassi RR; Kim HR; Li L; Spitz DR; Lokshin A; Kim JH
    Exp Cell Res; 2003 Aug; 288(1):21-34. PubMed ID: 12878156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells.
    Mazurek N; Byrd JC; Sun Y; Hafley M; Ramirez K; Burks J; Bresalier RS
    Cell Death Differ; 2012 Mar; 19(3):523-33. PubMed ID: 21941373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System.
    Corrado A; Aceto R; Silvestri R; Dell'Anno I; Ricci B; Miglietta S; Romei C; Giovannoni R; Poliseno L; Evangelista M; Vitiello M; Cipollini M; Garritano S; Giusti L; Zallocco L; Elisei R; Landi S; Gemignani F
    Thyroid; 2021 Jul; 31(7):1056-1066. PubMed ID: 33308024
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphorylated galectin-3 mediates tumor necrosis factor-related apoptosis-inducing ligand signaling by regulating phosphatase and tensin homologue deleted on chromosome 10 in human breast carcinoma cells.
    Mazurek N; Sun YJ; Liu KF; Gilcrease MZ; Schober W; Nangia-Makker P; Raz A; Bresalier RS
    J Biol Chem; 2007 Jul; 282(29):21337-48. PubMed ID: 17420249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
    Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
    Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-1 Modulates the Survival and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) Sensitivity in Human Hepatocellular Carcinoma Cells.
    Li J; Sun RR; Yu ZJ; Liang H; Shen S; Kan Q
    Cancer Biother Radiopharm; 2015 Oct; 30(8):336-41. PubMed ID: 26348206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR; Shankar S; Chen X; Asim M; Srivastava RK
    Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
    Voelkel-Johnson C; King DL; Norris JS
    Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional impact of Galectin-3 and TRAIL expression in breast cancer cells.
    Liu XH; Deng CX; Hu PC; Wang Y; Dong YH
    Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3626-3633. PubMed ID: 28925481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The TRAIL to targeted therapy of breast cancer.
    Rahman M; Pumphrey JG; Lipkowitz S
    Adv Cancer Res; 2009; 103():43-73. PubMed ID: 19854352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells.
    Oka N; Nakahara S; Takenaka Y; Fukumori T; Hogan V; Kanayama HO; Yanagawa T; Raz A
    Cancer Res; 2005 Sep; 65(17):7546-53. PubMed ID: 16140916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.
    Balan V; Nangia-Makker P; Schwartz AG; Jung YS; Tait L; Hogan V; Raz T; Wang Y; Yang ZQ; Wu GS; Guo Y; Li H; Abrams J; Couch FJ; Lingle WL; Lloyd RV; Ethier SP; Tainsky MA; Raz A
    Cancer Res; 2008 Dec; 68(24):10045-50. PubMed ID: 19074869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The differential sensitivity of Bc1-2-overexpressing human breast tumor cells to TRAIL or doxorubicin-induced apoptosis is dependent on Bc1-2 protein levels.
    Ruiz de Almodóvar C; Ruiz-Ruiz C; Muñoz-Pinedo C; Robledo G; López-Rivas A
    Oncogene; 2001 Oct; 20(48):7128-33. PubMed ID: 11704839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-hairpin RNA-induced suppression of adenine nucleotide translocase-2 in breast cancer cells restores their susceptibility to TRAIL-induced apoptosis by activating JNK and modulating TRAIL receptor expression.
    Jang JY; Jeon YK; Choi Y; Kim CW
    Mol Cancer; 2010 Sep; 9():262. PubMed ID: 20875141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
    BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired Resistance of ER-Positive Breast Cancer to Endocrine Treatment Confers an Adaptive Sensitivity to TRAIL through Posttranslational Downregulation of c-FLIP.
    Piggott L; Silva A; Robinson T; Santiago-Gómez A; Simões BM; Becker M; Fichtner I; Andera L; Young P; Morris C; Barrett-Lee P; Alchami F; Piva M; Vivanco MD; Clarke RB; Gee J; Clarkson R
    Clin Cancer Res; 2018 May; 24(10):2452-2463. PubMed ID: 29363524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.